• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

The KonLin Letter Issues Follow-Up Report on eFoodSafety.Com Inc. In Its July 2006 Issue; The KonLin Letter States That 'EFSF is on the Verge of Explosive Revenue Growth'

Posted on: Tuesday, 11 July 2006, 12:00 CDT

Patricia Ross-Gruden, president and CEO of eFoodSafety.com Inc. (OTCBB: EFSF), announced today that The KonLin Letter issued a Follow-Up Report on eFoodSafety.com Inc. in its July 2006 issue. The KonLin Letter reiterates its "Strong Buy" recommendation of EFSF stock.

According to Konrad Kuhn, editor of The KonLin Letter, Patricia Gruden has done a masterful job of repositioning the company and setting the stage for eFoodSafety.com Inc. to become a dominant player in the scar cream and diabetes markets, while bringing the company to the forefront with potential solutions in both the Lyme disease and bird flu arenas.

The KonLin Letter, a 25-year-old investment advisory newsletter noted for its fundamental and technical analysis of individual stocks and market movements, does not accept compensation for its analyses of selected companies. The report includes a review of the latest developments of the company, the company's market position and potential advantages, along with fundamentals and statistics.

Kuhn cited the following reasons for his July 2006 follow-up recommendation:

-- First quarter revenue for 2006-2007 should exceed the total revenue for all of the four quarters in Fiscal Year 2005-2006.

-- The bird flu formulation currently is in patent pending status and could be entering a multibillion-dollar market shortly. More news is anticipated on this product. Indications are that additional testing is ongoing.

-- The sales of Cinnergen(TM) from both its Direct Response Marketing Campaign and retail sales are exceeding initial expectations.

-- The Lyme's formulation is undergoing human clinical trials and initial results indicate it could become the only treatment known to treat long-term chronic Lyme disease.

-- In fiscal year 2006-2007, the anti-acne product sales are expected to commence with long-term sales estimated in the $200 million range. It is anticipated that a high-profile celebrity and brand name will be announced soon.

"I've said it before and I'll say it again, never before have I seen a company with such huge upside potential in so many multibillion-dollar arenas, in my 25-year history as a newsletter writer," stated Kuhn.

About KonLin Research & Analysis Corp.

The KonLin Letter, www.KonLin.com, chooses low-priced stocks to analyze, with an emphasis on emerging growth and special situations poised for explosive price appreciation. The KonLin Letter has constantly been one of the leading publications on Wall Street. It has been rated one of the best-performing market letters in the nation, offering a unique service that each month recommends five low-priced selections, including a featured stock of the month. EFSF was the featured stock in the month of September 2005.

About eFoodSafety.com Inc.

eFoodSafety.com Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Big 6 Plus - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a nonprescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes. The company has recently entered into a joint venture agreement with CK41 Direct Inc. to launch an anti-acne skin care system, with a branded name and celebrity spokesperson to be announced in the near future.

Please visit the company's Web site at http://www.efoodsafety.com.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

Source: Business Wire

More News in this Category